GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Heron Therapeutics Inc. (APPAD) [hlAlert]

Rating:
Outperform
APPAD
up 167.41 %

Heron Therapeutics Inc. (HRTX) rated Outperform by Leerink Swann

Posted on: Monday,  Feb 3, 2014  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Heron Therapeutics Inc. (NASDAQ: HRTX) on 02/03/2014, when the stock price was $12.49.
Since then, Heron Therapeutics Inc. has gained 167.41% as of 01/19/2016's recent price of $33.40.
If you would have followed this Leerink Swann 's recommendation on HRTX, you would have gained 167.41% of your investment in 715 days.

A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company?s primary focus is on its lead product candidate, APF530, which completed a pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008. APF530 is designed to prevent CINV for at least five days and contains granisetron, a drug approved for the prevention of CINV. In addition to its lead drug candidate, A.P. Pharma has a pipeline of other product candidates that use its Biochronomer technology. One of these, APF112, incorporates the local anesthetic, mepivacaine. It is designed to provide up to 36 hours of post-surgical pain relief and to minimize the use of morphine-like drugs, or opiates, which are used in post-surgical pain management.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy